BSN Tracker

paliperidone

Brand: Invega, Invega Sustenna, Invega Trinza

⚠ BBW Beers Criteria Prototype: risperidone
Drug Class: second-generation antipsychotic (SGA)
Drug Family: antipsychotic
Subclass: benzisoxazole derivative
Organ Systems: cns

Mechanism of Action

Active 9-hydroxy metabolite of risperidone; blocks D2 and 5-HT2A receptors (SGA mechanism) plus alpha-1 and H1 receptors. Unlike risperidone, paliperidone is not significantly metabolized by CYP enzymes because it is already the active form, offering more predictable pharmacokinetics.

D2 dopamine receptor5-HT2A receptoralpha-1 adrenergic receptorH1 histamine receptor

Indications

  • schizophrenia
  • schizoaffective disorder
  • long-acting injectable (LAI) formulations for maintenance therapy

Contraindications

  • hypersensitivity to risperidone or paliperidone
  • QT prolongation

Adverse Effects

Common

  • EPS (dose-dependent)
  • hyperprolactinemia
  • somnolence
  • tachycardia
  • orthostatic hypotension
  • weight gain

Serious

  • NMS
  • tardive dyskinesia
  • QT prolongation
  • metabolic effects

Pharmacokinetics (ADME)

Absorption oral ER formulation releases drug over 24 hours via osmotic push; food increases Cmax by 50-60%
Distribution protein binding ~74%; Vd ~487 L
Metabolism limited hepatic metabolism; ~59% excreted unchanged renally — renal dose adjustment required
Excretion primarily renal (~80% unchanged)
Half-life 23 hours (oral); 25-49 days (LAI 1-month); 84-95 days (LAI 3-month)
Onset oral: days to weeks; LAI: weeks
Peak 24 hours (oral)
Duration oral: 24 hours; LAI: 1-3 months depending on formulation
Protein Binding 74%
Vd 487 L

Drug Interactions

Drug / Agent Mechanism Severity
carbamazepine (CYP3A4/P-gp inducer) decreases paliperidone levels ~37% moderate
QT-prolonging agents additive QT prolongation major
antihypertensives additive hypotension via alpha-1 blockade moderate

Nursing Considerations

  1. Paliperidone extended-release (ER) tablet osmotic shell is excreted intact in stool — reassure patients that seeing the tablet ghost in the stool is normal and does not indicate lack of absorption.
  2. Dose reduction is required in renal impairment; paliperidone is 59% renally cleared unchanged, unlike most antipsychotics.
  3. Long-acting injectable (Invega Sustenna) requires two loading doses (days 1 and 8 as deltoid injections) before transitioning to monthly dosing; this loading protocol is critical for maintaining therapeutic levels.
  4. Monitor prolactin levels in patients with breast tenderness, galactorrhea, menstrual irregularities, or sexual dysfunction — paliperidone causes significant hyperprolactinemia due to D2 blockade in the tuberoinfundibular pathway.

Clinical Pearls

  • Paliperidone has the most available long-acting injectable formulations (monthly and 3-monthly) among SGAs, making it particularly valuable for adherence management in schizophrenia.
  • Its minimal hepatic metabolism (largely renally excreted unchanged) makes it predictable in patients with hepatic impairment but requires dose adjustment in CKD.

Safety Profile

Pregnancy use-with-caution
Lactation avoid
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Long-acting Injectable (LAI) Formulations For Maintenance Therapy Schizoaffective Disorder Schizophrenia Second-generation Antipsychotic (SGA)
← Back to Medications